Collegium Pharmaceutical Inc (COLL)’s Ratio Roundup: Key Metrics for Trailing Twelve Months

Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.

As of close of business last night, Collegium Pharmaceutical Inc’s stock clocked out at $32.15, up 2.06% from its previous closing price of $31.50. In other words, the price has increased by $2.06 from its previous closing price. On the day, 0.88 million shares were traded. COLL stock price reached its highest trading level at $33.345 during the session, while it also had its lowest trading level at $31.371.


To gain a deeper understanding of COLL’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.31 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 3.41. For the most recent quarter (mrq), Quick Ratio is recorded 1.14 and its Current Ratio is at 1.21. In the meantime, Its Debt-to-Equity ratio is 2.84 whereas as Long-Term Debt/Eq ratio is at 2.01.

Jefferies Downgraded its Buy to Hold on January 04, 2024, whereas the target price for the stock was revised from $30 to $37.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 29 ’24 when Smith Thomas B sold 995 shares for $36.76 per share. The transaction valued at 36,580 led to the insider holds 63,409 shares of the business.

Dreyer Scott sold 10,000 shares of COLL for $364,270 on Feb 26 ’24. The EVP & Chief Commercial Officer now owns 138,918 shares after completing the transaction at $36.43 per share. On Jan 16 ’24, another insider, Dreyer Scott, who serves as the EVP & Chief Commercial Officer of the company, sold 23,560 shares for $32.28 each. As a result, the insider received 760,519 and left with 111,322 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, COLL now has a Market Capitalization of 1051796928 and an Enterprise Value of 1363740544. As of this moment, Collegium’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.39, and their Forward P/E ratio for the next fiscal year is 4.41. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 24.35. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.85 while its Price-to-Book (P/B) ratio in mrq is 4.73. Its current Enterprise Value per Revenue stands at 2.406 whereas that against EBITDA is 3.974.

Stock Price History:

The Beta on a monthly basis for COLL is 0.96, which has changed by 0.39600515 over the last 52 weeks, in comparison to a change of 0.2704494 over the same period for the S&P500. Over the past 52 weeks, COLL has reached a high of $40.95, while it has fallen to a 52-week low of $20.83. The 50-Day Moving Average of the stock is -14.23%, while the 200-Day Moving Average is calculated to be 9.23%.

Shares Statistics:

It appears that COLL traded 451.25K shares on average per day over the past three months and 566900 shares per day over the past ten days. A total of 32.71M shares are outstanding, with a floating share count of 32.23M. Insiders hold about 1.47% of the company’s shares, while institutions hold 117.99% stake in the company. Shares short for COLL as of 1714435200 were 6858723 with a Short Ratio of 15.20, compared to 1711584000 on 7118018. Therefore, it implies a Short% of Shares Outstanding of 6858723 and a Short% of Float of 25.900000000000002.

Earnings Estimates

A comprehensive evaluation of Collegium Pharmaceutical Inc (COLL) is underway, with the input of 3.0 analysts contributing to its current rating.On average, analysts expect EPS of $0.96 for the current quarter, with a high estimate of $1.52 and a low estimate of $0.62, while EPS last year was $0.34. The consensus estimate for the next quarter is $1.03, with high estimates of $1.59 and low estimates of $0.69.

Analysts are recommending an EPS of between $6.18 and $2.6 for the fiscal current year, implying an average EPS of $3.75. EPS for the following year is $5.37, with 4.0 analysts recommending between $7.26 and $3.78.

Revenue Estimates

In the current quarter, 6 analysts expect revenue to total $142.76M. It ranges from a high estimate of $144.8M to a low estimate of $141.05M. As of the current estimate, Collegium Pharmaceutical Inc’s year-ago sales were $138.4MFor the next quarter, 6 analysts are estimating revenue of $144.69M. There is a high estimate of $146.93M for the next quarter, whereas the lowest estimate is $142.5M.

A total of 6 analysts have provided revenue estimates for COLL’s current fiscal year. The highest revenue estimate was $590.18M, while the lowest revenue estimate was $580.5M, resulting in an average revenue estimate of $583.24M. In the same quarter a year ago, actual revenue was $566.77MBased on 6 analysts’ estimates, the company’s revenue will be $594.6M in the next fiscal year. The high estimate is $605.76M and the low estimate is $579.6M.

Most Popular

[the_ad id="945"]